First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors

By sjmartinez • February 19, 2025

Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. ESMO Open. 2025 Feb 17;10(3):104291. doi: 10.1016/j.esmoop.2025.104291. Epub ahead of print. PMID: 39965362.

Tags: advanced or metastatic solid tumors, anti-drug antibodies, anti-PD-1–IL-15 fusion, antibody–cytokine fusion molecule, Hematology/Oncology, phase I study, Publications

Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience[...]

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based[...]